Genetic subtypes of invasive bladder cancer

David McConkey, Woonyoung Choi, Colin P N Dinney

Research output: Contribution to journalReview article

Abstract

Purpose of review Recently completed cancer genomics projects identified intrinsic subtypes in muscle-invasive bladder cancers. Here we will describe the studies that led to their discovery and review their biological and clinical properties. Recent findings Whole genome mRNA expression profiling and unsupervised hierarchical cluster analyses identified intrinsic basal and luminal subtypes in muscle-invasive bladder cancers that are similar to the ones found in breast cancer. Tumors within each subtype have distinct responses to conventional cisplatin-based combination chemotherapy, and they contain gene expression signatures and DNA alterations that may render them vulnerable to clinically available targeted therapies. Summary Like their breast cancer counterparts, basal bladder cancers are characterized by poor clinical outcomes in the absence of effective systemic therapy, but a large fraction of them do respond to neoadjuvant chemotherapy, suggesting that the tumors should be managed aggressively. On the contrary, tumors that belong to the 'p53-like' subtype tend to be chemoresistant, so patients with these tumors should probably be managed differently. It seems likely that prospective identification of tumor intrinsic subtype membership could complement the use of DNA-based biomarkers to identify the groups of patients who will benefit the most from chemotherapy and targeted agents.

Original languageEnglish (US)
Pages (from-to)449-458
Number of pages10
JournalCurrent Opinion in Urology
Volume25
Issue number5
DOIs
StatePublished - Sep 1 2015
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Neoplasms
Breast Neoplasms
Drug Therapy
Muscles
DNA
Genomics
Combination Drug Therapy
Transcriptome
Cisplatin
Cluster Analysis
Biomarkers
Genome
Messenger RNA
Therapeutics

Keywords

  • Basal
  • Claudin-low
  • Epithelial-to-mesenchymal transition
  • Luminal
  • PDL1
  • TCGA

ASJC Scopus subject areas

  • Urology

Cite this

Genetic subtypes of invasive bladder cancer. / McConkey, David; Choi, Woonyoung; Dinney, Colin P N.

In: Current Opinion in Urology, Vol. 25, No. 5, 01.09.2015, p. 449-458.

Research output: Contribution to journalReview article

@article{e3acb35f08d045e2affc7ad650909da0,
title = "Genetic subtypes of invasive bladder cancer",
abstract = "Purpose of review Recently completed cancer genomics projects identified intrinsic subtypes in muscle-invasive bladder cancers. Here we will describe the studies that led to their discovery and review their biological and clinical properties. Recent findings Whole genome mRNA expression profiling and unsupervised hierarchical cluster analyses identified intrinsic basal and luminal subtypes in muscle-invasive bladder cancers that are similar to the ones found in breast cancer. Tumors within each subtype have distinct responses to conventional cisplatin-based combination chemotherapy, and they contain gene expression signatures and DNA alterations that may render them vulnerable to clinically available targeted therapies. Summary Like their breast cancer counterparts, basal bladder cancers are characterized by poor clinical outcomes in the absence of effective systemic therapy, but a large fraction of them do respond to neoadjuvant chemotherapy, suggesting that the tumors should be managed aggressively. On the contrary, tumors that belong to the 'p53-like' subtype tend to be chemoresistant, so patients with these tumors should probably be managed differently. It seems likely that prospective identification of tumor intrinsic subtype membership could complement the use of DNA-based biomarkers to identify the groups of patients who will benefit the most from chemotherapy and targeted agents.",
keywords = "Basal, Claudin-low, Epithelial-to-mesenchymal transition, Luminal, PDL1, TCGA",
author = "David McConkey and Woonyoung Choi and Dinney, {Colin P N}",
year = "2015",
month = "9",
day = "1",
doi = "10.1097/MOU.0000000000000200",
language = "English (US)",
volume = "25",
pages = "449--458",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Genetic subtypes of invasive bladder cancer

AU - McConkey, David

AU - Choi, Woonyoung

AU - Dinney, Colin P N

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Purpose of review Recently completed cancer genomics projects identified intrinsic subtypes in muscle-invasive bladder cancers. Here we will describe the studies that led to their discovery and review their biological and clinical properties. Recent findings Whole genome mRNA expression profiling and unsupervised hierarchical cluster analyses identified intrinsic basal and luminal subtypes in muscle-invasive bladder cancers that are similar to the ones found in breast cancer. Tumors within each subtype have distinct responses to conventional cisplatin-based combination chemotherapy, and they contain gene expression signatures and DNA alterations that may render them vulnerable to clinically available targeted therapies. Summary Like their breast cancer counterparts, basal bladder cancers are characterized by poor clinical outcomes in the absence of effective systemic therapy, but a large fraction of them do respond to neoadjuvant chemotherapy, suggesting that the tumors should be managed aggressively. On the contrary, tumors that belong to the 'p53-like' subtype tend to be chemoresistant, so patients with these tumors should probably be managed differently. It seems likely that prospective identification of tumor intrinsic subtype membership could complement the use of DNA-based biomarkers to identify the groups of patients who will benefit the most from chemotherapy and targeted agents.

AB - Purpose of review Recently completed cancer genomics projects identified intrinsic subtypes in muscle-invasive bladder cancers. Here we will describe the studies that led to their discovery and review their biological and clinical properties. Recent findings Whole genome mRNA expression profiling and unsupervised hierarchical cluster analyses identified intrinsic basal and luminal subtypes in muscle-invasive bladder cancers that are similar to the ones found in breast cancer. Tumors within each subtype have distinct responses to conventional cisplatin-based combination chemotherapy, and they contain gene expression signatures and DNA alterations that may render them vulnerable to clinically available targeted therapies. Summary Like their breast cancer counterparts, basal bladder cancers are characterized by poor clinical outcomes in the absence of effective systemic therapy, but a large fraction of them do respond to neoadjuvant chemotherapy, suggesting that the tumors should be managed aggressively. On the contrary, tumors that belong to the 'p53-like' subtype tend to be chemoresistant, so patients with these tumors should probably be managed differently. It seems likely that prospective identification of tumor intrinsic subtype membership could complement the use of DNA-based biomarkers to identify the groups of patients who will benefit the most from chemotherapy and targeted agents.

KW - Basal

KW - Claudin-low

KW - Epithelial-to-mesenchymal transition

KW - Luminal

KW - PDL1

KW - TCGA

UR - http://www.scopus.com/inward/record.url?scp=84942591993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942591993&partnerID=8YFLogxK

U2 - 10.1097/MOU.0000000000000200

DO - 10.1097/MOU.0000000000000200

M3 - Review article

C2 - 26218634

AN - SCOPUS:84942591993

VL - 25

SP - 449

EP - 458

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 5

ER -